Grunnet Mie, Mau-Sørensen Morten, Brünner Nils
Department of Oncology, Rigshospitalet, Copenhagen, Denmark.
Scand J Gastroenterol. 2013 Aug;48(8):899-905. doi: 10.3109/00365521.2013.812235. Epub 2013 Jul 8.
The value of Tissue Inhibitor of MetalloProteinase-1 (TIMP-1) as a biomarker in patients with gastric cancer (GC) is widely debated. The aim of this review is to evaluate available literature describing the association between levels of TIMP-1 in tumor tissue and/or blood and the prognosis of patients suffering from GC.
Using the search words 'TIMP-1', 'Gastric Cancer' and 'Tumor marker', a search was carried out on PubMed. Exclusion criteria were articles never published in English, articles from before 1995 and articles evaluating tumor markers other than TIMP-1 in GC.
Of initially 50 articles, 17 were found to fulfill the selection criteria and relevant for this study. The 17 articles evaluated the usefulness of TIMP-1 levels in tumor tissue or blood, respectively, as a prognostic marker in patients with GC.
A literature search showed that elevated protein levels of TIMP-1 in either tumor tissue extracts or in plasma from patients suffering from GC associates with poor patient outcome.
金属蛋白酶组织抑制剂-1（TIMP-1）作为胃癌（GC）患者生物标志物的价值存在广泛争议。本综述的目的是评估现有文献，这些文献描述了肿瘤组织和/或血液中TIMP-1水平与GC患者预后之间的关联。
使用关键词“TIMP-1”、“胃癌”和“肿瘤标志物”在PubMed上进行检索。排除标准为从未以英文发表的文章、1995年以前的文章以及评估GC中除TIMP-1以外的肿瘤标志物的文章。
最初检索到的50篇文章中，有17篇符合入选标准且与本研究相关。这17篇文章分别评估了肿瘤组织或血液中TIMP-1水平作为GC患者预后标志物的有用性。
文献检索表明，GC患者肿瘤组织提取物或血浆中TIMP-1蛋白水平升高与患者预后不良相关。
